DK0666746T3 - Delta5-androstener, som er nyttige til at fremme vægtbevarelse eller vægttab, og behandlingsmåde - Google Patents

Delta5-androstener, som er nyttige til at fremme vægtbevarelse eller vægttab, og behandlingsmåde

Info

Publication number: DK0666746T3
Authority: DK; Denmark
Prior art keywords: beta; delta; androstene; androstenes; alpha
Prior art date: 1993-09-02

Application number

DK94927309T

Other languages

Danish (da)

English (en)

Inventor

Henry A Lardy

Ieva L Reich

Wei Yong

Original Assignee

Humanetics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-02

Filing date

1994-09-01

Publication date

2001-10-01

1994-09-01 Application filed by Humanetics Corp filed Critical Humanetics Corp

2001-10-01 Application granted granted Critical

2001-10-01 Publication of DK0666746T3 publication Critical patent/DK0666746T3/da

Links

230000001737 promoting effect Effects 0.000 title abstract 2
150000001443 androstenes Chemical class 0.000 title 1
230000014759 maintenance of location Effects 0.000 title 1
230000004580 weight loss Effects 0.000 title 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 3
SBNLPRGISFUZQE-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical class C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 SBNLPRGISFUZQE-VMXHOPILSA-N 0.000 abstract 2
238000004260 weight control Methods 0.000 abstract 2
OEVZKEVBDIDVOI-FMKNUBLKSA-N androst-5-ene-3beta,7alpha,17beta-triol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](O)C=C21 OEVZKEVBDIDVOI-FMKNUBLKSA-N 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000003163 gonadal steroid hormone Substances 0.000 abstract 1
230000007062 hydrolysis Effects 0.000 abstract 1
238000006460 hydrolysis reaction Methods 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
125000000468 ketone group Chemical group 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Pretreatment Of Seeds And Plants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK94927309T 1993-09-02 1994-09-01 Delta5-androstener, som er nyttige til at fremme vægtbevarelse eller vægttab, og behandlingsmåde DK0666746T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12315193A	1993-09-02	1993-09-02
PCT/US1994/009852 WO1995006472A1 (fr)	1993-09-02	1994-09-01	Δ5-androstenes utiles pour favoriser le maintien ou la perte de poids et methode de traitement

Publications (1)

Publication Number	Publication Date
DK0666746T3 true DK0666746T3 (da)	2001-10-01

Family

ID=22406999

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94927309T DK0666746T3 (da)	1993-09-02	1994-09-01	Delta5-androstener, som er nyttige til at fremme vægtbevarelse eller vægttab, og behandlingsmåde

Country Status (11)

Country	Link
EP (1)	EP0666746B1 (fr)
JP (1)	JP3143749B2 (fr)
AT (1)	ATE202707T1 (fr)
AU (1)	AU7679494A (fr)
CA (1)	CA2148373A1 (fr)
DE (1)	DE69427634T2 (fr)
DK (1)	DK0666746T3 (fr)
ES (1)	ES2160128T3 (fr)
GR (1)	GR3036666T3 (fr)
PT (1)	PT666746E (fr)
WO (1)	WO1995006472A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000511404A (ja)	1996-04-09	2000-09-05	ビー・テイー・ジー・インターナシヨナル・リミテツド	神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用
US6153606A (en) *	1998-10-16	2000-11-28	Humanetics Corporation	Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US6667299B1 (en)	2000-03-16	2003-12-23	Hollis-Eden Pharmaceuticals, Inc.	Pharmaceutical compositions and treatment methods
AU2002351933A1 (en) *	2001-11-08	2003-05-19	Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung	Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5028631A (en) *	1987-11-25	1991-07-02	Schwartz Arthur G	Homoandrostan-17-one and homoandrosten-17-ones
EP0547151B1 (fr) *	1990-08-29	2002-11-20	Humanetics Corporation	Procede de traitement favorisant la perte de poids, employant delta 5-androstene substitue

1994
- 1994-09-01 DK DK94927309T patent/DK0666746T3/da active
- 1994-09-01 AU AU76794/94A patent/AU7679494A/en not_active Abandoned
- 1994-09-01 AT AT94927309T patent/ATE202707T1/de not_active IP Right Cessation
- 1994-09-01 EP EP94927309A patent/EP0666746B1/fr not_active Expired - Lifetime
- 1994-09-01 WO PCT/US1994/009852 patent/WO1995006472A1/fr active IP Right Grant
- 1994-09-01 JP JP07508253A patent/JP3143749B2/ja not_active Expired - Fee Related
- 1994-09-01 ES ES94927309T patent/ES2160128T3/es not_active Expired - Lifetime
- 1994-09-01 DE DE69427634T patent/DE69427634T2/de not_active Expired - Fee Related
- 1994-09-01 PT PT94927309T patent/PT666746E/pt unknown
- 1994-09-01 CA CA002148373A patent/CA2148373A1/fr not_active Abandoned
2001
- 2001-09-18 GR GR20010401526T patent/GR3036666T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
GR3036666T3 (en)	2001-12-31
JP3143749B2 (ja)	2001-03-07
ATE202707T1 (de)	2001-07-15
JPH08503491A (ja)	1996-04-16
WO1995006472A1 (fr)	1995-03-09
PT666746E (pt)	2001-11-30
EP0666746A1 (fr)	1995-08-16
EP0666746B1 (fr)	2001-07-04
CA2148373A1 (fr)	1995-03-09
ES2160128T3 (es)	2001-11-01
AU7679494A (en)	1995-03-22
DE69427634T2 (de)	2002-05-08
DE69427634D1 (de)	2001-08-09
EP0666746A4 (fr)	1998-01-21

Similar Documents

Publication	Publication Date	Title
DE69133158D1 (de)	2003-01-02	Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
ATE390932T1 (de)	2008-04-15	Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE69940975D1 (de)	2009-07-23	Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
NO985975L (no)	1999-02-18	Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
ATE195530T1 (de)	2000-09-15	17-ether und thioether von 4-aza-steroiden
DK0584136T3 (da)	2000-05-22	Bestemmelse af peptidmotiver på MHC-molekyler
ATE136540T1 (de)	1996-04-15	Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
NO940638L (fr)	1994-05-02
ES2150152T3 (es)	2000-11-16	Nuevos derivados de esteres de nitrito/nitrato esteroideos utiles como farmacos antiinflamatorios.
UA87959C2 (ru)	2009-09-10	Применение экстрактов с vitex agnus castus, которые содержат фитоэстроген, который селективно модулирует бета-рецепторы эстрогена
KR960701648A (ko)	1996-03-28	Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)
PT78743A (de)	1984-07-01	1-alkyl-androsta-1,4-dien-3,17-dione verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DK0666746T3 (da)	2001-10-01	Delta5-androstener, som er nyttige til at fremme vægtbevarelse eller vægttab, og behandlingsmåde
DE68918944D1 (de)	1994-11-24	Künstliche rezeptor-analoge.
SE8204874D0 (sv)	1982-08-25	Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
DE69010025D1 (de)	1994-07-28	Verfahren zur Herstellung von 14-Alpha-hydroxy-4-androsten-3,6,17, trion.
ES2037278T3 (es)	1995-04-01	Tratamiento de la esterilidad.
NZ318272A (en)	2000-10-27	Glucocorticoid enhancement of gene expression
MX9706283A (es)	1998-02-28	Nuevos antibioticos de polieno, 3874 hi a h6, procedimientos para su preparacion y empleo.
EP0559706A4 (fr)	1994-02-09
DE68928646D1 (de)	1998-05-28	Natriuretisches hormon
NO872331L (no)	1987-12-07	Farmasoeytiske preparater for behandling av bakterielle infeksjoner.
NO873381L (no)	1987-08-12	Fremgangsmaate for fremstilling av 4-androsten-3,7-dion og 1,4-androstadien-3,7-dion.
ES2015772A6 (es)	1990-09-01	Procedimiento e obtencion de nuevos derivados del 5-fluorouracilo, concretamente los n1-acil-sustituidos-n3-orto-toluil-5-fluorouracilo.
ATE186048T1 (de)	1999-11-15	Vitalethin und seine anwendung in zellkultur und therapie